Editorial

The steady growth of *Pharmaceutical Research* requires continuous editorial adjustments to accomodate the increasing manuscript flow. It is my pleasure to introduce Professor Gordon Amidon as the Associate Editor, Pharmaceutics and Drug Delivery (PDD). Dr. Amidon, currently Professor of Pharmaceutics at the University of Michigan, Ann Arbor, is an accomplished scientist with interests in prodrugs and membrane transport phenomena. He will evaluate manuscripts and foster journal activity in the PDD area as one of the strongest components of *Pharmaceutical Research*. In this capacity he will also represent the PDD section of the AAPS, but his role transcends national boundaries to encompass worldwide research in the highly active PDD field. Welcome aboard, Gordon.

Our preference to engage active scientists as Editors, with numerous other commitments, will make it necessary to appoint more Associate Editors in specialty fields. Over the next several years, we intend to engage Associate Editors for the scientific areas of each of the AAPS sections, covering all of the pharmaceutical sciences. The selection process will include an active role of the AAPS sections, but also an open search for qualified personalities in the scientific community in general.

Meanwhile, the international focus of the journal has also been strengthened. Professor Breimer as the Regional Editor responsible for Europe plays a pivotal role in maintaining a worldwide standard and perspective of the journal. He will work with the Associate Editors in specialty fields at his discretion, deciding whether a European manuscript is reviewed in Europe by referees or handled by a specialty Associate Editor. Turning to the other side of the world, I am proud to welcome five eminent Japanese scientists as new members of the Editorial Advisory Board. They are:

Professor Tetsuya Kamataki, Sapporo; drug metabolism, function and molecular biology of cytochrome P-450 and related enzymes.

Professor Masahiro Nakano, Kumamoto; clinical pharmacokinetics, biopharmaceutics, clinical pharmacy, anticancer drugs.

Professor Tetsuo Osa, Sendai; analytical chemistry, electrochemical analysis, membrane ion sensors.

Professor Tomio Segawa, Hiroshima; molecular pharmacology, neuropeptides.

Professor Akio Tsuji, Tokyo; analytical chemistry, immuno assays, chemiluminescence.

The selection of these advisors reflects the growing number of manuscripts from Japan, and their areas of expertise broaden the spectrum of disciplines in *Pharmaceutical Research*. We very much appreciate their willingness to assist in the editorial process. Because of his recent retirement, Professor Takagi has resigned from the Advisory Board. I am very grateful for his participation from the inception of *Pharmaceutical Research*, and I hope that Professor Takagi will continue to contribute to the journal from his emeritus position.

For the interest of prospective authors for *Pharmaceutical Research*, I wish to point out a change in the manuscript format (see Instructions to Contributors). We have increased the usual page limits for Letters (4 pages), Technical Notes (8 pages), Reports (12 pages), and full-length Research Articles and Reviews (24 pages), in order to reflect more accurately the actual manuscript length of submitted papers. The page limit increase for Reports as the main manuscript category in *Pharmaceutical Research* will make it easier to fit original research work into this format. I am very pleased that the average quality of recently submitted manuscripts has increased, so that the actual rejection rate has slightly decreased. To accomodate all publishable articles, we have now increased the number of pages to be published in 1989 by more than 30%.

The full support of a major scientific organization and the willingness of renowned scientists to serve as Editors are the hallmark of a successful journal today. The AAPS is well on its way to become a major force in the pharmaceutical area, and we now have a number of active scientists as Editors of *Pharmaceutical Research*. Our main goal is to provide a publication forum, worldwide, for a broad spectrum of scientific disciplines at the crossroads of the physicochemical, biological, and clinical sciences. The first steps toward this goal have been taken.

Wolfgang Sadée Editor